April 4, 2018 / 8:15 PM / 18 days ago

BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA

April 4 (Reuters) - Paratek Pharmaceuticals Inc:

* PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA

* PDUFA ACTION DATE IN OCTOBER 2018

* IN NDA ACCEPTANCE LETTER, FDA STATED THAT NO FILING OR POTENTIAL REVIEW ISSUES WERE IDENTIFIED AT THE TIME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below